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Introduction
"How long have I got?" is often asked by patients when they are diagnosed with advanced cancer however prognosis in this setting is challenging. The prognostic value of tumour stage and pathological characteristics is well defined in early stage cancer. However its value for prognosis in advanced disease is much diminished with a ceiling level reached as patients with metastatic disease vary widely in terms of prognosis. Poor prediction of likely outcome may result in sub-optimal care, whereas reliable prognostic information may help guide clinicians to decide the appropriate cancer treatment.
In advanced cancer, measures of performance status (e.g. Karnofsky Despite extensive efforts, few other reliable prognostic factors have been identified in patients with advanced cancer, which can be used to guide treatment and care plans. There remains a continuing and urgent need to identify reliable and routinely available prognostic factors in patients with advanced cancer.
Based on a systematic review of the literature, Maltoni and colleagues proposed that there was 4 These prognostic parameters have been extensively studied and in some cases prognostic scoring systems have been developed.(11) However, limitations of prognostic markers are acknowledged, such as subjective measures (symptoms, clinical prediction, performance status) or assessing multiple parameters.
Therefore, these are not incorporated into routine clinical practice.(4) PS remains the gold standard and the most widely used parameter in prognosis in advanced cancer.
To date, the role of biomarkers of systemic inflammation in cancer prognosis, has largely been ignored in clinical practice.(12, 13) Systemic inflammation has been shown to predict survival, independent of tumour stage and pathological characteristics, in patients with a variety of common solid tumours. (14) There are various parameters that can be used to measure systemic inflammation and one method, termed the Glasgow Prognostic Score (mGPS), uses a combination of CRP and albumin (Table 1) . (15) In the mGPS, CRP is utilized as a positive marker of systemic inflammation whilst albumin is both a negative marker of inflammation and a measure of lean (muscle) tissue.
The mGPS has been examined in over 60,000 cancer patients (including homogenized groups e.g. lung cancer), has been shown to have independent prognostic value and is superior to other markers of the systemic inflammatory response in cancer prognosis.(16) However work to date using the mGPS has not reported on patients near the end of life which are a complex group and difficult to stratify, thus the usefulness of the mGPS in this group of patients is not clear. Furthermore, a comparison with gold standard prognostic markers (such as performance status) has not been carried out.
In a single-centre pilot study, examining the mGPS in 100 patients with advanced cancer (median survival eight weeks), the mGPS was reported to have independent prognostic value.(17) However this cohort was small and the clinical utility of the mGPS in conjunction with existing prognostic markers, such as performance status, remains to be established.
The hypothesis of the present study is that the mGPS may have a role either alone or in combination, with other prognostic markers, such as PS in advanced cancer. In turn, more accurate prognostic information may complement clinical impression and allow anti-cancer therapy to be given more appropriately in patients with advanced cancer.
Research. The present study had three aims: Firstly, to compare the prognostic value of established clinical factors (such as performance status, symptom measures) with the systemic inflammation-based Glasgow Prognostic Score (mGPS). Secondly, to assess if performance status in combination with mGPS is more powerful than either alone. Finally, to assess both of these aspects in a test sample before validation in an independent sample.
Research. 
Materials and Methods

Study Population
Analysis was undertaken on two international biobanks of adult cancer patients; termed test sample and validation sample. Eligible patients were 18 years of age with either metastatic or locally advanced disease.
In both studies, a convenience sample of patients was recruited from across the following settings: oncology wards, palliative care units/hospices, surgical wards and outpatient departments. Patients who could not communicate in the primary language at the study centre were excluded. All patents provided written informed consent and ethical approval was given.
Procedure and Assessment
In both studies, patient demographics and performance status (PS), primary cancer site and presence of metastases were recorded. Symptom and quality of life variables were recorded using the EORTC QLQ- 
Biomarkers
CRP and albumin were used as biomarkers of the inflammatory response and were taken by venous blood sampling at entry points to both studies. The limit of detection of CRP was <5mg/l -all samples (CRP and albumin) were analysed at a central laboratory. The mGPS was calculated as follows:
• CRP < 10mg/l and any albumin level = 0
• CRP > 10mg/l and any albumin level = 1
Research. • CRP > 10mg/l and albumin < 35 g/l = 2 These cut-offs are based on previous studies examining the mGPS and not derived from the present analysis. (16) Statistical Analysis BMI and mGPS were grouped using the thresholds described above. EORTC QLQ-C30 scores were analysed as discrete categories representing underlying continuous constructs.(22) Karnofsky PS was transformed as described by Ma et al into ECOG performance status groupings, to simplify analysis and interpretation. (23) All statistical testing was conducted at the 5% level and 95% confidence intervals (CI) are reported throughout.
The survival time, defined as the number of months from study entry until death, or censored if alive at follow-up date, was calculated. Survival curves were plotted using Kaplan-Meier methods and the log rank test applied. Survival analysis was carried out using Cox's proportional-hazards model and hazard ratios (HR) were calculated. To allow for possible nonlinearity, PS and mGPS were analysed using dummy indicators to represent different categories of these two variables.
Multivariate survival analysis was performed using a stepwise backward procedure to derive a final model of the variables that had a significant independent relationship with survival. To remove a variable from the model, the corresponding P-value had to be >0.10. Stratification by primary cancer site was undertaken in the survival analysis.
All analyses were done on the test sample before being undertaken on the validation sample. All analyses were performed in SPSS Version 18.0 (SPSS Inc).
Results
Data were available on 1825 patients in the test sample and 631 patients in the validation sample, across a total of eleven countries. Patient demographics are shown in Table 1 . All patients had cancer with the most common primary cancer types being gastro-intestinal, pulmonary cancer and breast cancer.
Test sample: 1524 patients (84%) had metastatic disease at study entry and 281(15.4%) were on active treatment (chemotherapy). The median age was 63 years (IQR 54-71) and 931 patients were male (51%). The median PS (ECOG) was 2.0 (IQR 2-3). The minimum and median follow-up for survivors was 4.9 months and 30.5 months, respectively. At the time of cessation of data collection, 224 patients were alive and 1601 had died. The median survival was 3.2 months (1.0-10.6).
Validation sample: All patients had metastatic or locally advanced cancer at study entry and 458 (72.6%) were on active treatment. The median age was 64 years (IQR 56-71) and 237 patients were male (53%). The median PS (ECOG) was 2 (IQR (1-2). The minimum and median follow-up for survivors was 10.1 months and 14.7 months, respectively. At the time of cessation of data collection, 160 patients were alive and 471 had died. The median survival was 7.03 months (IQR 2.5-7.33).
The relationship between clinicopathological factors and survival is shown in PS and mGPS independently predicted survival and were the strongest predictors of survival in the test sample. This was confirmed in the validation sample. Furthermore PS and mGPS were consistently similar across both datasets. EORTC patient reported outcomes were not consistent prognostic factors across both datasets.
The relationship between mGPS, PS and survival in the test sample is shown in Figure 1 . Increasing mGPS was significantly associated with poorer survival (p<0.001). Worsening performance status was associated with poorer survival (p<0.001). These findings were supported in the validation sample; Figure   2 . Increasing mGPS was significantly associated with poorer survival (p<0.001). Worsening performance status was associated with poorer survival (p<0.001).
The relationship between the mGPS, PS and survival at 3 months in the test sample is shown in Table 3 . Survival at 3 months varied from 82% (mGPS 0) to 39% (mGPS 2) and from 75% (PS 0-1) to 15%(PS 4). When used in combination survival ranged from 88% (mGPS 0, PS 0-1) to 10% (mGPS 2, PS 4), p<0.001. In all patients, using 3 month mortality as an endpoint, the area under the receiver operator curve was for mGPS: 0.667 (95% CI, 0.64-0.69, p<0.001) and PS: 0.703 (95% CI, 0.68-0.73, p<0.001).
The relationship between the mGPS, PS and survival at 3 months is confirmed in the validation sample, shown in Table 4 . Survival at 3 months varied from 87% (mGPS 0) to 46% (mGPS 2) and from 88% (PS 0-1) to 23% (PS 4). When used in combination survival ranged from 93% (mGPS 0, PS 0-1) to 18% (mGPS 2, PS 3), p<0.001. In all patients, using 3 month mortality as an endpoint, the area under the receiver operator curve was for mGPS: 0.720 (95% CI, 0.67-0.77, p<0.001) and PS: 0.717 (95% CI, 0.67-0.76, p<0.001).
Discussion
The results of the present study show that perfomance status and the systemic inflammation based score, the mGPS, are strong prognostic factors in advanced cancer. The mGPS independently predicts survival in patients with advanced cancer and this supports our pilot work examining the mGPS. Of particular interest, however, is that the mGPS performed similarly to PS, in terms of survival prediction (based on Hazard Ratio's). Furthermore the the utility of the mGPS in isolation, and an approach combining mGPS and PS, has been tested and validated, in two large independent datasets. These findings may have an impact in oncological practice.
Performance status has been shown to be an independent prognostic factor in patients with advanced cancer and remains the gold standard; a finding supported by the present study. (5) The KPS was the first commonly used tool of this type and more recently the ECOG performance status tool was developed and is very similar, but simpler, for quantifying the functional status of patients with cancer.(1) However, one of the challenges when using performance status as a prognostic measure, is that it is subjective and may not be findings support that the mGPS has independent prognostic value in a variety of clinical scenarios (including patients on chemotherapy) and is unlikely to be affected by this as few patients change their systemic inflammatory response status before or after treatment (29, 30) .
The present study's findings are insufficient to support that PS as a prognostic marker is superceded by the mGPS. Furthermore, biochemical markers should never dictate patient care with the adage of "treating the patient, not the results" never being more appropriate than in prognosis. However, PS in combination with an objective score (such as the mGPS) is of interest and is more appropriate for clinical use, than isolated biomarkers. The present study shows that the mGPS can be used with PS, and improves the accuracy of survival prediction of PS alone as the combination effectively predicts survival at 3 months ranging from 88% to 10%. Therefore, this easy to obtain combination (mGPS-PS) may be a simple procedure that can be used to predict outcome in patients with advanced cancer.
Prognosis in cancer is an essential and currently unmet need; a crude artform based mostly on clinicians' intuition/experiences, which are often erroneous, optimistic, informal and subjective. (6) Improved prognostic accuracy may have several benefits in advanced cancer.
Firstly, chemotherapy or radiotherapy is becoming increasingly commonplace late in the disease trajectory in advanced cancer: one study showed that 18.5% of patients were still receving chemotherapy within two weeks of death.(31) However the decision as to give such treatments is often challenging and is often made after careful discussion about possible risks and benefits with the patient, taking into consideration the likely prognosis. Clinician predicted survival remains suboptimal with one study of approximately 1500 advanced patients showing that only one in four estimates of life expectancy by clinicians was accurate.(32) Furthermore, patients prefer a realistic and individualized approach regarding prognosis in cancer to enable them to make decisions regarding having treatment. (33, 34) The findings of the present study provide additional information to enable clinicians and patients to make a more informed choice about the appropriateness of chemotherapy or radiotherapy in advanced disease. This may translate to anti-cancer therapy being directed towards those in whom it is likely to benefit versus those in whom no benefit and/or potential harm is likely.
and also as to the purpose of that admission (e.g. end of life care). The decision to treat potentially life limiting conditions near the end of life (e.g. lower respiratory tract infection) may also be influence by improved prognostic accuracy.
Finally, the concept of a good death, is usually one where a patient dies free from distressing symptoms and once all goodbyes and personal affairs have been addressed. (35, 36) An accurate knowledge of prognosis may aid this and also help health professionals in their discussion with patients.
Limitations
A limitation is that no direct comparison was performed with other prognosis systems and further studies to clarify differences between prognosis systems in patients with advanced cancer are required. Another important consideration is that there is evidence that tumour cells produce pro-inflammatory/ inflammatory cytokines and that tumour burden is associated with an increased release of such cytokines. Therefore it may be postulated that tumour burden relates to the pro-inflammatory state and may affect biomarkers of inflammation. However, it is also recognised that resection of the primary tumour does not significantly alter systemic inflammatory response status. (16, 29, 30) This would suggest that the primary defect is in the dysregulation of the immune cell and inflammatory responses in the patient with cancer, supporting the role of inflammatory biomarkers in prognostication.
Future Work
In the present study it was clear from both the test and validation datasets that PS and the mGPS were correlated and therefore are likely to capture some of the same elements that determine survival. Future work should develop the objective mGPS such that it may displace the subjective performance status in the prediction of survival in patients with advanced cancer. If this was achieved it would represent a paradigm shift in the clinical management of these difficult to treat patients. The present study represents a major step forward in this goal. 
Conclusion
The present study demonstrates that the mGPS predicts survival in advanced cancer independently and performs well compared to PS in terms of prognostic power. These findings highlight a potential role for the mGPS (objective measure) in combination with PS (subjective measure), with these acting synergistically, predicting survival effectively. This new approach would also enable measures of systemic inflammation to be a part of the routine, clinical prediction of survival in patients with advanced cancer. 7, 8 A prognostic tool combining mGPS and PS could guide clinicians in the appropriate cancer treatment for their patients and further work examining this in practice would be of interest. . These findings extend previous observations in other disease states such as cardiovascular disease that has established the independent prognostic value of inflammatory biomarkers in patient risk stratification. 
